Related Experiment Video
Updated: Jun 28, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management
Paige Hargis1, Hannah Baker1, Brett Wiesen1
1Division of Urology, University of Colorado, Aurora, CO, USA.
The Urologic Clinics of North America
|June 26, 2026
Summary
Novel therapies offer new hope for high-risk non-muscle-invasive bladder cancer (HR-NMIBC) management, especially for BCG-unresponsive cases. Approved and emerging treatments show promising response rates and disease control, expanding treatment options beyond traditional Bacillus Calmette-Guérin (BCG).
Area of Science:
- Uro-oncology
- Bladder cancer research
- Clinical trial analysis
Background:
- High-risk non-muscle-invasive bladder cancer (HR-NMIBC) has a significant risk of recurrence and progression.
- Radical cystectomy is often necessary for advanced HR-NMIBC.
- Intravesical Bacillus Calmette-Guérin (BCG) is the standard first-line treatment but has limitations.
Purpose of the Study:
- To review key clinical trials in HR-NMIBC management.
- To focus on therapeutic advancements for BCG-unresponsive bladder cancer.
- To highlight novel intravesical and systemic agents.
Main Methods:
- Summary of pivotal clinical trials for HR-NMIBC.
- Emphasis on studies involving novel intravesical and systemic therapies.
- Analysis of treatment outcomes for BCG-unresponsive disease.
Main Results:
- Approved intravesical and systemic agents show significant response rates.
- Durable disease control is achievable in selected HR-NMIBC patient populations.
- Emerging therapies and combination treatments expand therapeutic options.
Conclusions:
- Novel therapeutic strategies are transforming HR-NMIBC management.
- Effective options now exist for patients with BCG-unresponsive bladder cancer.
- Continued research into new agents and combinations is crucial.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...